Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biopharmaceuticals, nutraceuticals, cosmetics, agrochem and food/beverage industries, has signed a two-year collaborative research and development agreement with Dr. Adrienne Denese, MD, PhD. Creator of the award-winning SkinScience Labs, Denese is a recognized QVC icon, industry Visionary, anti-aging pioneer and founder and president of Dr. Denese SkinScience, one of the most successful, highly rated, and longest-lasting skincare lines in the history of QVC. According to the agreement, PBI and Dr. Denese SkinScience will work together to develop skincare projects to pursue, developing statements of work (“SOW”) with approved budgets, timetables and remuneration formulas for both companies. The two companies will begin by focusing on the potential for PBI’s unique Ultra Shear Technology(TM) (“UST”) nanoemulsification platform to enhance existing and develop new SkinScience skincare products. “From 2019 to 2021, Dr. Denese averaged close to $20 million per year in total sales,” said Pressure BioSciences president and CEO Richard T. Schumacher in the press release. “In 2022, with help from new channel partner Costco, sales are expected to increase significantly. The launch of a new generation of products processed by PBI’s patented UST platform, for the first-time ever in the cosmeceuticals area, is planned for 2023, which we expect to result in a very fulfilling and exciting year for Dr. Denese and her loyal customers — and for PBI. . . . Although final determination of the order of development of these new and enhanced products is yet to be announced, both Dr. Denese SkinScience and PBI understand that these are potential game-changers in an industry whose 2021 global market size was estimated to be over $130 billion. We look at this partnership as an opportunity for multimillion-dollar accretive revenue growth for both companies over the next two years, with the potential to dramatically enhance the growth trajectory and profitability of both Dr. Denese SkinScience and PBI for years to come.”
To view the full press release, visit https://ibn.fm/Nq1XL
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating, or pressure cycling technology (“PCT”) hydrostatic pressure. PCT is a patented, enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions (e.g., cell lysis, biomolecule extraction) safely and reproducibly. The company’s primary focus is on the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter bioterror applications. Additionally, major new market opportunities have emerged for the use of PBIO’s pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. to allow entry into the biopharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company website at www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
